A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Key claim: Bomedemstat (MK-3543) is hypothesized to be superior to best available therapy in achieving durable clinicohematologic response in ET patients with inadequate response to or intolerance of hydroxyurea.
Abstract
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Why this matters
The HU-resistant/intolerant ET population is the most therapeutically active second-line niche in MPN trials, and bomedemstat’s Phase 3 program (MK-3543-006 in this post-HU setting plus MK-3543-007 frontline) is the most advanced LSD1 inhibitor effort in this subtype. A positive readout would establish a mechanistically novel non-interferon, non-anagrelide option for ET patients who fail hydroxyurea, directly altering the second-line decision tree.